More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
More and more data are being collected on people and in healthcare, patients have to believe that the data being collected is for their good and with the goal of improving their care, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
How can healthcare balance the pros and cons consumers see when they think about all the data being collected on them?
Well, the data is out there. I think there is a sense of the public trust having been violated and at the same time everybody acknowledges—I’ve got a lot of friends, especially younger generation, like “Yeah, they collect it and I don’t care. I have Alexa and I have Google in my home, and I know they’re collecting data on me and I don’t care.”
So, is healthcare data really any different? Or is the fact that we’re using social data that we can get on a patient to improve the care that we’re delivering, is that a bad thing? Or is that a good thing? That’s the kind of question that should be raised and debated, but in general, one of the guiding principles there is beneficence, and the good intention behind having that data in order to render better care is certainly noble.
So, at the end of the day, in healthcare, I think we win the ethical discussion and we are certainly in a better position than say the big industry tech giants that are using it for profit.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More